Renu Gupta
- Annual prevalence and treatment estimates of nontuberculous mycobacterial pulmonary disease in Europe: A NTM-NET collaborative studyBy Dirk Wagner, Jakko van Ingen, Jennifer Adjemian, Christoph Lange, D. Rebecca Prevots, David Griffith, Jack Gallagher, Renu Gupta and Charles HaworthDirk Wagner1Division of Infectious Diseases and Center for Chronic Immunodeficiency, University Medical Center, Freiburg, GermanyJakko van Ingen2Department of Medical Microbiology, Radboud University Medical Center, Nijmegen, NetherlandsJennifer Adjemian3Epidemiology Unit, Laboratory of Clinical Infectious Diseases, National Institute of Allergy and Infectious Diseases, Bethesda, MD,Christoph Lange4Division of Clinical Infectious Diseases, Research Center Borstel, Borstel, GermanyD. Rebecca Prevots3Epidemiology Unit, Laboratory of Clinical Infectious Diseases, National Institute of Allergy and Infectious Diseases, Bethesda, MD,David Griffith5Pulmonary and Critical Care Division, The University of Texas Health Science Center, Tyler, TX,Jack Gallagher6Department of Analytics, Clarity Pharma Research, LLC, Spartanburg, SC,Renu Gupta7Clinical Development, Insmed Incorporated, Monmouth Junction, NJ,Charles Haworth8Centre for Lung Infection, Papworth Hospital, Cambridge, United Kingdom
- Comparison of treatment practices for nontuberculous mycobacterial pulmonary disease in Japan, Europe, and United StatesBy Jakko van Ingen, Jennifer Adjemian, Kozo Morimoto, Dirk Wagner, Christoph Lange, Charles Haworth, Jack Gallagher, D. Rebecca Prevots, Renu Gupta and David GriffithJakko van Ingen1Department of Medical Microbiology, Radboud University Medical Center, Nijmegen, NetherlandsJennifer Adjemian2Epidemiology Unit, Laboratory of Clinical Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD,Kozo Morimoto3Respiratory Disease Center, Fukujuji Hospital, Tokyo, JapanDirk Wagner4Division of Infectious Diseases and Center for Chronic Immunodeficiency, University Medical Center, Freiburg, GermanyChristoph Lange5Division of Clinical Infectious Diseases, Research Center Borstel, Borstel, GermanyCharles Haworth6Cambridge Centre for Lung Infection, Papworth Hospital, Cambridge, United KingdomJack Gallagher7Department of Analytics, Clarity Pharma Research, LLC, Spartanburg, SC,D. Rebecca Prevots2Epidemiology Unit, Laboratory of Clinical Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD,Renu Gupta8Clinical Development, Insmed Incorporated, Monmouth Junction, NJ,David Griffith9Pulmonary and Critical Care Division, The University of Texas Health Science Center, Tyler, TX,
- Interim data from a long-term safety, tolerability, and efficacy study of liposomal amikacin for inhalation in cystic fibrosis patients with chronic pseudomonas aeruginosa infectionBy Diana Bilton, Tacjana Pressler, Isabelle Fajac, John Clancy, Dorota Sands, Predrag Minic, Marco Cipolli, Mario La Rosa, Ivanka Galeva, Amparo Solé, Nicole Mayer-Hamblett, Scott Constantine, Renu Gupta and Michael KonstanDiana Bilton1Department of Respiratory Medicine, Royal Brompton Hospital, London, United KingdomTacjana Pressler2Department of Pediatrics, CF Arikace Study Group, Monmouth Junction, NJ,Isabelle Fajac3Department of Physiology, CF Arikace Study Group, Monmouth Junction, NJ,John Clancy2Department of Pediatrics, CF Arikace Study Group, Monmouth Junction, NJ,Dorota Sands2Department of Pediatrics, CF Arikace Study Group, Monmouth Junction, NJ,Predrag Minic4Department of Pulmonology, CF Arikace Study Group, Monmouth Junction, NJ,Marco Cipolli5Cystic Fibrosis Center, CF Arikace Study Group, Monmouth Junction, NJ,Mario La Rosa2Department of Pediatrics, CF Arikace Study Group, Monmouth Junction, NJ,Ivanka Galeva6Infant Department, Pediatric Clinic, CF Arikace Study Group, Monmouth Junction, NJ,Amparo Solé7Adult Cystic Fibrosis Unit, CF Arikace Study Group, Monmouth Junction, NJ,Nicole Mayer-Hamblett2Department of Pediatrics, CF Arikace Study Group, Monmouth Junction, NJ,Scott Constantine8Clinical Operations, Insmed Incorporated, Monmouth Junction, NJ,Renu Gupta9Clinical Development, Insmed Incorporated, Monmouth Junction, NJ,Michael Konstan2Department of Pediatrics, CF Arikace Study Group, Monmouth Junction, NJ,
- Treprostinil prodrugs for pulmonary arterial hypertension evaluated in cAMP profiling studies in live CHO-K1 cellsBy Kuan-Ju Chen, Jane Ong, Vlad Malinin, Franziska Leifer, Donna Omiatek, Zhili Li, Richard Chapman, Walter Perkins and Renu GuptaKuan-Ju Chen1Clinical Research & Operations, Insmed Inc., Monmouth Junction, NJ,Jane Ong1Clinical Research & Operations, Insmed Inc., Monmouth Junction, NJ,Vlad Malinin1Clinical Research & Operations, Insmed Inc., Monmouth Junction, NJ,Franziska Leifer1Clinical Research & Operations, Insmed Inc., Monmouth Junction, NJ,Donna Omiatek1Clinical Research & Operations, Insmed Inc., Monmouth Junction, NJ,Zhili Li1Clinical Research & Operations, Insmed Inc., Monmouth Junction, NJ,Richard Chapman1Clinical Research & Operations, Insmed Inc., Monmouth Junction, NJ,Walter Perkins1Clinical Research & Operations, Insmed Inc., Monmouth Junction, NJ,Renu Gupta1Clinical Research & Operations, Insmed Inc., Monmouth Junction, NJ,
Buying books on this site
Purchases made on this website are of electronic books only.
About the ERS books
The ERS Monograph is the quarterly book series from the European Respiratory Society. Each Monograph covers a specific area of respiratory medicine, providing in-depth reviews that give clinicians at all levels a concise, comprehensive guide to symptoms, diagnosis and treatment.
The ERS Handbooks are compact guides to broad areas of the respiratory field. Launched in 2010, the series now covers adult, paediatric and sleep respiratory medicine, includes a companion volume of self-assessment questions and features the ERS Practical Handbooks.